Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,397Revenue $M149Net Margin (%)-108.8Z-Score-3.9
Enterprise Value $M1,245EPS $-1.4Operating Margin %-80.7F-Score5
P/E(ttm))0Cash Flow Per Share $-1.0Pre-tax Margin (%)-107.3Higher ROA y-yN
Price/Book010-y EBITDA Growth Rate %0Quick Ratio3.7Cash flow > EarningsY
Price/Sales8.95-y EBITDA Growth Rate %29.1Current Ratio3.8Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-37.3Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M127ROI % (ttm)-196.7Gross Margin Increase y-yY

Gurus Latest Trades with NKTR

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NKTRPRIMECAP Management 2014-03-31 Add0.04%$11.35 - $14.96
($13.16)
$ 11-16%Add 24.29%15,534,086
NKTRPRIMECAP Management 2013-12-31 Add0.03%$8.96 - $12.56
($10.75)
$ 112%Add 25.56%12,498,386
NKTRPRIMECAP Management 2013-09-30 Add0.03%$10.541 - $13.96
($12.36)
$ 11-11%Add 31.41%9,953,856
NKTRPRIMECAP Management 2012-12-31 Reduce-0.05%$5.99 - $10.83
($8.09)
$ 1136%Reduce -29.07%6,469,856
NKTRJean-Marie Eveillard 2011-12-31 Sold Out -0.003%$4.22 - $5.62
($4.9)
$ 11124%Sold Out0
NKTRJean-Marie Eveillard 2011-09-30 Buy $4.98 - $7.65
($5.97)
$ 1184%New holding, 125000 sh.125,000
NKTRPRIMECAP Management 2011-03-31 Add0.02%$8.58 - $12.85
($10.43)
$ 116%Add 41.43%6,128,100
NKTRPRIMECAP Management 2010-06-30 Add0.04%$11.25 - $15.58
($13.3)
$ 11-17%Add 82.73%3,579,750
NKTRPRIMECAP Management 2010-03-31 Add0.03%$9.15 - $15.52
($12.67)
$ 11-13%Add 106.54%1,959,000
NKTRPRIMECAP Management 2009-12-31 Add0.01%$8.07 - $9.84
($9.01)
$ 1122%Add 104.73%948,500
NKTRPRIMECAP Management 2009-09-30 Add0.01%$5.89 - $10.47
($7.71)
$ 1143%Add 210.94%463,300
NKTRPRIMECAP Management 2009-06-30 Add$5.02 - $6.94
($5.94)
$ 1185%Add 50.51%149,000
NKTRGeorge Soros 2008-03-31 Sold Out -0.07%$6.27 - $7.29
($6.8)
$ 1162%Sold Out0
NKTRJean-Marie Eveillard 2008-03-31 Sold Out -0.01%$6.27 - $7.29
($6.8)
$ 1162%Sold Out0
NKTRJean-Marie Eveillard 2007-12-31 Add0.01%$5.57 - $8.27
($6.6)
$ 1167%Add 150%125,000
NKTRGeorge Soros 2007-12-31 Reduce-0.05%$5.57 - $8.27
($6.6)
$ 1167%Reduce -28.24%241,397
NKTRGeorge Soros 2007-09-30 Add0.02%$7.95 - $9.51
($8.7)
$ 1126%Add 26.87%336,397
NKTRJean-Marie Eveillard 2007-09-30 Buy $7.95 - $9.51
($8.7)
$ 1126%New holding, 50000 sh.50,000
NKTRGeorge Soros 2007-03-31 Reduce-0.13%$11.26 - $14.63
($12.9)
$ 11-15%Reduce -45.45%364,897
NKTRGeorge Soros 2006-12-31 Add0.1%$14.38 - $16.84
($15.5)
$ 11-29%Add 30%668,897
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NKTR is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
NKTR PRIMECAP Management 2014-03-3115,534,08612.230.21+24.29%
Premium Most recent portfolio changes are included for Premium Members only!


NKTR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
WHITFIELD ROY ADirector 2013-08-05Sell12,500$12.41-11.36view
KUEBLER CHRISTOPHER ADirector 2013-08-05Sell12,500$12.41-11.36view
KUEBLER CHRISTOPHER ADirector 2012-09-27Sell12,500$10.663.19view
WINGER DENNIS LDirector 2012-09-14Buy5,000$9.1819.83view
CHESS ROBERTDirector 2012-07-13Sell24,001$8.529.41view
CHESS ROBERTDirector 2011-03-08Sell4,500$922.22view
CHESS ROBERTDirector 2010-05-10Sell35,000$13.95-21.15view
Labrucherie Gil MSVP & General Counsel 2009-05-12Sell395$5.5797.49view
Thomsen Jillian B.VP & Chief Accounting Officer 2009-05-12Sell201$5.5797.49view
Labrucherie Gil MSVP & General Counsel 2008-11-14Sell401$4.37151.72view

Press Releases about NKTR :

    Quarterly/Annual Reports about NKTR:

    News about NKTR:

    Articles On GuruFocus.com
    Weekly Guru Bargains Highlights: AKAM, NKTR, LOGI, FFIV, LCC Apr 16 2011 
    Weekly Guru Bargains Highlights: AMSC, LOGI, NKTR, DAL, AIG Apr 09 2011 
    Four Guru Stocks near New Lows: FBN, HOME, NKTR, PETS Feb 07 2011 
    MannKind: Deja Vu for the FDA and Afrezza Dec 29 2010 
    Nektar Therapeutics Reports Operating Results (10-Q) Nov 04 2010 
    Nektar Therapeutics Reports Operating Results (10-Q) Jul 29 2010 
    Nektar Therapeutics Reports Operating Results (10-Q) May 06 2010 
    cooldecency99 note on NKTR May 01 2010 
    Small-Cap Biotech Stocks: Why This Sector Is Set for a Huge Year Jan 06 2010 
    Nektar Therapeutics Reports Operating Results (10-Q) Nov 05 2009 


    More From Other Websites
    Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After... Jul 22 2014
    NEKTAR THERAPEUTICS Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Jun 27 2014
    Cara Therapeutics appoints Medve Chief Medical Officer Jun 24 2014
    Data Published in the New England Journal of Medicine Demonstrate that Naloxegol Improved... Jun 19 2014
    The Zacks Analyst Blog Highlights: Idenix, Achillion Pharmaceuticals, Nektar, Orexigen, Celgene,... Jun 19 2014
    NEKTAR THERAPEUTICS Files SEC form 8-K, Other Events Jun 18 2014
    Regado Biosciences: The Revolyxis Revolution Has Begun Jun 17 2014
    Nektar Therapeutics (NKTR) in Focus: Stock Rises 10.77% Jun 16 2014
    A Nektar Victory Jun 14 2014
    Relief for Nektar after AADPAC Voting Jun 13 2014
    [$$] Two Undervalued Biopharmas to Buy Now Jun 13 2014
    3 Stocks Driving The Drugs Industry Higher Jun 13 2014
    [$$] Nektar Shares Rise on FDA Panel Recommendation Jun 12 2014
    US FDA ADVISORY COMMITTEE RECOMMENDS NO CARDIOVASCULAR OUTCOMES TRIAL FOR PERIPHERALLY-ACTING... Jun 12 2014
    Panel does not back CV safety trials for OIC drugs, Reuters says Jun 12 2014
    FDA panel advises against large opioid-constipation drug trials Jun 12 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide